<!DOCTYPE html>
<html lang="en-US">
<meta charset="UTF-8">

<title>OB/GYN Referenced</title>
<meta name="theme-color" content="#000000" />
<meta name="description" content="Uterine Leiomyomas">
<meta name="viewport" content="width=device-width, initial-scale=1">
<link rel="shortcut icon" href="favicon.ico" type="image/x-icon">
<link rel="manifest" href="manifest.json">
<link rel="stylesheet" href="css/w3.css">
<link rel="stylesheet" href="css/hg.css">


<body onload="SetUpPage()">

    <header id="MyHeader" class="hg-NavBar">
        <a id="bkbtn" class="hg-BackButton" href="javascript:void(0)" onclick="goBack()"></a>
        <a id="hmbrgbtn" class="hg-HamBtn" href="javascript:void(0)" onclick="SideBarOpen()"></a>
        <span id="titbar" class="hg-NavBarTitle"></span>
    </header>

    <nav class="hg-SideBar" id="mySidebar"></nav>

    <div class="hg-OverLay  " onclick="SideBarClose()" title="close side menu" id="myOverlay"></div>

    <div class="hg-Content">

        <main class="hg-InfoContent">
            <h1 class="hg-h1PageTitle">Uterine Leiomyomas</h1>


            <h2 class="hg-h2SectionTitle">Background</h2>

            <section class="accordian">
                <button onclick="AccToggle('figleisuc')" class="hg-accBtn">FIGO leiomyoma subclassification:<span
                        id="figleisuc_c" class="hg-NavLinkChevron"></span></button>
                <div id="figleisuc" class="hg-accDivMain">
                    <img src="gyn_uterine_leiomyomas_classification.jpg" alt="Uterine leiomyomas subclassification."
                        class="hg-responsiveImage">
                    <P class=" hg-accNoteBlank">Source: Munro M.G., Critchley H.O., Broder M.S., Fraser I.S. The FIGO
                        Classification System (“PALM-COEIN”) for causes of abnormal uterine bleeding in non-gravid women
                        in the reproductive years, including guidelines for clinical investigation. Int J Gynaecol
                        Obstet. 2011; 113: 3-13</P>
                    <P class="hg-accNote">Describes relationship of leiomyoma to endometrial and serosal
                        surfaces.<sup>1</sup></P>
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('lieoutsymplk')" class="hg-accBtn">Symptoms:<span id="lieoutsymplk_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="lieoutsymplk" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Bleeding symptoms (AUB-L)<sup>1</sup>
                        </li>
                        <li>Bulk symptoms:
                            <ul>
                                <li>Pelvic pressure, frequency of urination, constipation.<sup>1</sup></li>
                            </ul>
                        </li>
                    </ul>
                </div>
            </section>

            <h2 class="hg-h2SectionTitle">Treatment</h2>

            <section class="accordian">
                <button onclick="AccToggle('medrxbldsw')" class="hg-accBtn">Medical treatment for bleeding
                    symptoms.<span id="medrxbldsw_c" class="hg-NavLinkChevron"></span></button>
                <div id="medrxbldsw" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Oral gonadotropin-releasing hormone antagonists with hormonal add-back therapy:<sup>1</sup>
                            <ul>
                                <li>Oriahnn:<sup>1</sup>
                                    <ul>
                                        <li>Twice daily:<sup>3</sup>
                                            <ul>
                                                <li>Elagolix 300 mg, estradiol 1 mg and norethindrone acetate 0.5 mg
                                                    capsule in the morning.</li>
                                                <li>Elagolix 300 mg capsule in the evening.</li>
                                            </ul>
                                        </li>
                                        <li>Approved for AUB-L for up to 24 months.<sup>3</sup></li>
                                        <li>Use non-hormonal contraception during treatment and for one week after
                                            discontinuing.<sup>3</sup></li>
                                    </ul>
                                    <P class="hg-accNote">Elagolix (Orilissa)</P>
                                </li>
                                <li>Myfembree:<sup>1</sup>
                                    <ul>
                                        <li>Once daily:<sup>4</sup>
                                            <ul>
                                                <li>Relugolix 40 mg, 1 mg estradiol and 0.5 mg norethindrone acetate
                                                    once daily </li>
                                            </ul>
                                        </li>
                                        <li>Approved for AUB-L for up to 24 months.<sup>4</sup></li>
                                        <li>May help bulk symptoms as well.<sup>1</sup></li>
                                        <li>Use non-hormonal contraception during treatment and for one week after
                                            discontinuing.<sup>4</sup></li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                        <li>52-mg LNG-IUD levonorgestrel-releasing intrauterine devices.<sup>1</sup></li>
                        <li>Combined hormonal contraceptives, progestin-only pills and depot medroxyprogesterone
                            acetate.<sup>1</sup></li>
                        <li>Tranexamic acid.<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('medrxbothy')" class="hg-accBtn">Medical treatment for bleeding and bulk
                    symptoms:<span id="medrxbothy_c" class="hg-NavLinkChevron"></span></button>
                <div id="medrxbothy" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Gonadotropin-releasing hormone agonists (leuprolide acetate) with or without add-back
                            hormonal
                            therapy.<sup>1</sup>
                            <ul>
                                <li>3.75 mg IM monthly / 11.25 mg IM every 12 weeks.<sup>5</sup></li>
                                <li>Use non-hormonal contraception during treatment.<sup>5</sup></li>
                                <li>Common add-back regimen:
                                    <ul>
                                        <li>Oral conjugated estrogen 0.625 mg and norethindrone acetate 2.5–5.0 mg
                                            daily.<sup>1</sup></li>
                                    </ul>
                                </li>
                                <li>Duration of use limits:
                                    <ul>
                                        <li>Short term treatment to "bridge" to other treatments.<sup>1</sup></li>
                                        <li>6 months <b>total</b> without add-back therapy.<sup>1,5</sup></li>
                                        <li>12 months <b>total</b> with add-back therapy.<sup>1,5</sup></li>
                                    </ul>
                                </li>
                            </ul>
                        </li>
                        <li>Possibly Myfembree (see above).<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('leioauypr')" class="hg-accBtn">Procedures:<span id="leioauypr_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="leioauypr" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Uterine artery embolization.<sup>1</sup></li>
                        <li>Endometrial ablation<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <section class="accordian">
                <button onclick="AccToggle('leioauyprs')" class="hg-accBtn">Surgical options:<span id="leioauyprs_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="leioauyprs" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li>Myomectomy.<sup>1</sup></li>
                        <li>Hysterectomy.<sup>1</sup></li>
                    </ul>
                </div>
            </section>

            <section class="accordian hg-accSectionRelTopics">
                <button onclick="AccToggle('leiowdcRelLinks')" class="hg-accBtn">Related topics:<span
                        id="leiowdcRelLinks_c" class="hg-NavLinkChevron"></span></button>
                <div id="leiowdcRelLinks" class="hg-accDivMain">
                    <ul class=hg-accUl>
                        <li><a href="gyn_abnormal_uterine_bleeding_classification.html">Abnormal Uterine Bleeding
                                Classification</a></li>
                    </ul>
                </div>
            </section>


            <section class="accordian hg-accSectionRef">
                <button onclick="AccToggle('utleijyRefs')" class="hg-accBtn">References:<span id="utleijyRefs_c"
                        class="hg-NavLinkChevron"></span></button>
                <div id="utleijyRefs" class="hg-accDivMain">
                    <ol class="hg-accOlRef">
                        <li>Management of symptomatic uterine leiomyomas. ACOG Practice Bulletin No. 228. American
                            College of Obstetricians and Gynecologists. Obstet Gynecol 2021;137:e100–15.</li>
                        18,2020.</li>
                        <li>Options for prevention and management of menstrual bleeding in adolescent patients
                            undergoing cancer treatment. ACOG Committee Opinion No. 817. American College of
                            Obstetricians and Gynecologists. Obstet Gynecol 2021;137:e7–15.</li>
                        <li>https://www.rxabbvie.com/pdf/oriahnn_pi.pdf</li>
                        <li>https://www.myovant.com/wp-content/uploads/2021/05/Approved-MYFEMBREE-PI-and-PPI_26May2021.pdf
                        </li>
                        <li>http://www.lupron.com/</li>
                    </ol>
                </div>
            </section>


        </main>

        <div class="hg-AddContent">
            <p class="hg-AddSmall ">AD</p>
            <p class="hg-AddLarge  ">AD</p>
        </div>

    </div>

    <script defer src="script.js"></script>
    <script defer src="script-aux.js"></script>

</body>

</html>